Medical & Healthcare Professionals

With the advanced liposomal formulation to help enhance product penetration into the skin, LMX4® contains only 4% lignocaine. This unique formulation reduces the risks of redness and adverse side effects. Erythema is seen in only 2.9% of LMX4® patients and it has effectively and safely numbed the skin of millions of patients in the USA.

LMX4® is a fast, effective and safe numbing cream that can be used before cosmetic treatments including:

• Injectables and fillers
• Dermabrasion
• Dermal rolling
• Skin needling
• Epilation-laser, IPL, Waxing
• Laser tattoo removal
• Laser skin resurfacing
• Tattoo pain
• Body piercing
  
  

LMX4® can also be used to help numb the skin before superficial medical procedures including:

• Immunisations
• Simple excisions
• Insertion of IV canulation
• Blood sampling
  
  

To order LMX4® for your clinic, please contact Dermocosmètica:

AUS: +61 (0)3 9354 0898 
NZ: +64 0800 603 906  
E: customerservice@dermocosmetica.com.au
W:  www.dermocosmetica.com.au

References

1) Taddio et al, CMAJ 2005; 172(13): 1691–95.
2) Koh et al, Pediatric Anesthesia 2004; 14: 977–98.
3) LMX4® Summary of Product Characteristics, TGA August 2011.
4) Nestor, Journal of Drugs in Dermatology 2006, 5(7): 618–20.
5) Mezei M in Hsieh DS, ed. Drug permeation enhancement. New York, NY: Marcel Dekker Inc; 1994:171–98.
6) Kleiber et al, Pediatrics 2002; 100(4).
7) Emla Product Information March 2010.
8) Local AnGel RCH Melbourne, Consumer Health Information, 22 November 2002.
EMLA® is a registered trademark of AstraZeneca.